NAIROBI,Kenya Nov 21 – German pharmaceutical company Boehringer Ingelheim says it has screened more than 250,000 Kenyans for diabetes and hypertension and enrolled over 20,000 patients on treatment since 2022, as it steps up efforts to tackle late diagnosis of non-communicable diseases.
The company, through its Access to Healthcare programme, has been taking screening services closer to communities, particularly in rural and underserved areas where access to medical facilities remains a challenge.
George Kuria, Boehringer Ingelheim’s Sustainable Development for Generations and Access to Health Manager for Sub-Saharan Africa, said the initiative was designed to identify patients early and link those diagnosed with the conditions to treatment and continued medical care.
“So far, we have been able to screen more than 250,000 patients since we started, and we have been able to put on treatment more than 20,000 patients in this programme,” Kuria said in an interview with Capital FM.
Implemented in partnership with healthcare providers, including Zuri Health, the programme uses community outreach clinics and screening camps to reach people who might otherwise go without routine medical checks.
Kuria attributed the high number of undiagnosed cases to poor health-seeking habits, the cost of treatment, limited access to medical facilities and inadequate public awareness about non-communicable diseases (NCDs).



